The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Prodrug Strategies in Anticancer Chemotherapy
Abstract
The majority of clinically approved anticancer drugs are characterized by a narrow therapeutic window that results mainly from a high systemic toxicity of the drugs in combination with an evident lack of tumor selectivity. Besides the development of suitable galenic formulations such as liposomes or micelles, several promising prodrug approaches have been followed in the last decades with the aim of improving chemotherapy. In this review we elucidate the two main concepts that underlie the design of most anticancer prodrugs: drug targeting and controlled release of the drug at the tumor site. Consequently, active and passive targeting using tumor‐specific ligands or macromolecular carriers are discussed as well as release strategies that are based on tumor‐specific characteristics such as low pH or the expression of tumor‐associated enzymes. Furthermore, other strategies such as ADEPT (antibody‐directed enzyme prodrug therapy) and the design of self‐eliminating structures are introduced. Chemical realization of prodrug approaches is illustrated by drug candidates that have or may have clinical importance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Carbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
Tolcher, A. W., Ochoa, L., Hammond, L. A., Patnaik, A., Edwards, T., Takimoto, C., Smith, L., de Bono, J., Schwartz, G., Mays, T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.137 · Cited by 206
The Design of Inhibitors for Medicinally Relevant Metalloproteins
Jacobsen, F. E., Lewis, J. A., & Cohen, S. M. (2007) · ChemMedChem · doi:10.1002/cmdc.200600204 · Cited by 132
Cited by
Wang, J., Sánchez-Roselló, M., Aceña, J. L., del Pozo, C., Sorochinsky, A. E., Fustero, S., Soloshonok, V. A., & Liu, H. (2014) · Chemical Reviews · doi:10.1021/cr4002879 · Cited by 4,847
Photosensitizers with Aggregation‐Induced Emission: Materials and Biomedical Applications
Hu, F., Xu, S., & Liu, B. (2018) · Advanced Materials · doi:10.1002/adma.201801350 · Cited by 859
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Self‐Immolative Spacers: Kinetic Aspects, Structure–Property Relationships, and Applications
Alouane, A., Labruère, R., Le Saux, T., Schmidt, F., & Jullien, L. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500088 · Cited by 379
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268
“Prodrug strategies are currently under investigation in order to implement specific prodrug activation/action [152].”
Background
Metadata
- Authors
- Kratz, F., Müller, I. A., Ryppa, C., & Warnecke, A.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2008-01-03
- Volume
- 3
- Issue
- 1
- Pages
- 20-53
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W1989658721
- Cited by
- 486
- References
- 6
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
